Cite
Label-Free Imaging Analysis of Patient-Derived Cholangiocarcinoma Organoids after Sorafenib Treatment.
MLA
Koch, Michael, et al. “Label-Free Imaging Analysis of Patient-Derived Cholangiocarcinoma Organoids after Sorafenib Treatment.” Cells (2073-4409), vol. 11, no. 22, Nov. 2022, p. 3613. EBSCOhost, https://doi.org/10.3390/cells11223613.
APA
Koch, M., Nickel, S., Lieshout, R., Lissek, S. M., Leskova, M., van der Laan, L. J. W., Verstegen, M. M. A., Christ, B., & Pampaloni, F. (2022). Label-Free Imaging Analysis of Patient-Derived Cholangiocarcinoma Organoids after Sorafenib Treatment. Cells (2073-4409), 11(22), 3613. https://doi.org/10.3390/cells11223613
Chicago
Koch, Michael, Sandra Nickel, Ruby Lieshout, Susanna M. Lissek, Martina Leskova, Luc J. W. van der Laan, Monique M. A. Verstegen, Bruno Christ, and Francesco Pampaloni. 2022. “Label-Free Imaging Analysis of Patient-Derived Cholangiocarcinoma Organoids after Sorafenib Treatment.” Cells (2073-4409) 11 (22): 3613. doi:10.3390/cells11223613.